Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Data

Health Data

Aitia

Colin Hill

shahid yatoo

Zena Sfeir Gehchan (She/Her)

So-Youn Shin

Mitchell Rosen

McLaren Gould

Ken Levine

Joe Donahue

Jeanne Latourelle

Jan Berger

QIAN DU

Charles Homan

Bruce Church

The Engineering Team at Aitia is responsible for developing, optimizing, and maintaining the technological infrastructure and software solutions that drive the company's Causal AI and Digital Twin platforms. This includes designing and implementing high-performance computational systems, ensuring seamless integration of multi-omic data, and supporting the deployment and scaling of applications across cloud environments. The team collaborates closely with other departments to advance drug discovery efforts in oncology, neurodegenerative disorders, and immunology.

Engineering Team

Leadership Team

Business Development

Engineering Team

About

Team members

Other teams at Aitia

Leadership Team

Business Development